You are not currently logged in.
Access JSTOR through your library or other institution:
Mefloquine Is Highly Efficacious against Chloroquine-Resistant Plasmodium vivax Malaria and Plasmodium falciparum Malaria in Papua, Indonesia
Jason D. Maguire, Krisin, Hariyani Marwoto, Thomas L. Richie, David J. Fryauff and J. Kevin Baird
Clinical Infectious Diseases
Vol. 42, No. 8 (Apr. 15, 2006), pp. 1067-1072
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4463787
Page Count: 6
Preview not available
Background. During the period of 1996-1999, we prospectively monitored 243 Javanese adults and children after arriving in Papua, Indonesia, and microscopically documented each new case of malaria by active surveillance. Methods. In a randomized, open-label, comparative malaria treatment trial, 72 adults and 50 children received chloroquine for each incident case of malaria, and 74 adults and 47 children received mefloquine. Results. Among 975 primary treatment courses, the cumulative 28-day curative efficacies were 26% and 82% for chloroquine against Plasmodium falciparum malaria and Plasmodium vivax malaria, respectively. Mefloquine cure rates were far superior (96% against P. falciparum malaria and 99.6% against P. vivax malaria). Conclusions. Mefloquine is a useful alternative treatment for P. vivax malaria and P. falciparum malaria in areas such as Papua, where chloroquine is still recommended as the first-line therapeutic agent.
Clinical Infectious Diseases © 2006 Oxford University Press